Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I own 100,000 shares of CVBT/VT and I am part of the 5%. I despise the new management because of their hostile take over. This didn't have to happen. I'm now supporting Shittya because they don't have any patents and have the best blue hair advertising campaign ever
I won my first game of DANOPOLY last night.
It was difficult but I managed to run 13 corporations into the ground and lose everything.
I did land on the mail order bride space and although slightly more attractive than Mrs. M, I had to return her for a partial refund.
I had to cheat to win but I felt that was in the spirit of the Games namesake. Ripping off other players.
I wont tell you which anonymous message board poster I chose as my playing piece. I switch between multiple when I play, just like this games namesake.
I did come across a new Chance card while playing.
"Strike luck at the local bingo, score $100 investment in Zhittya"
I did get sent to jail and was not able to pass go for driving my playing piece at excessive speeds through too many fields of children playing though. I had to pay $100 for endangering the public.
Question 10: Of the many false rumors floated over the years regarding Venturis Therapeutics (formerly Cardiovascular Biotherapeutics or CVBT), which one turned out to actually be true?
(For reasons revealed below, you'll learn this is a particularly timely question.)
A. Venturis/CVBT was about to go public again “soon”, after many years of being de-listed.
B. Venturis/CVBT was “imminently” about to close on an 8-figure investment from Asia.
C. The clinical trials would be re-starting “next year”.
D. Some major industry company was looking closely at Venturis and a partnering deal was imminent.
E. A very high profile investor was “about” to make a very large investment in Venturis/CVBT.
F. Venturis Therapeutics was going to lose a 7-figure judgment at the hands of its former CEO.
G. Calvin Wallen’s trial by the U.S. government for allegedly stealing $14 million from his previous company was based on corruption and/or a profound miscarriage of justice, and was imminently about to be settled.
(You will note this is a particularly timely question for our quiz, and the reason why is explained below where the correct answer is revealed.)
This is part of our new Venturis Therapeutics educational trivia series. Unlike our cheap imitators who lack a single original thought in their minimally-educated brains, ours is an educational and fun exercise for the whole family while we're mostly not social distancing anymore (and are now sorry we didn't).
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156608105
The correct answer is: (F). Yes, while rumors were floating that in the binding arbitration case Dan Montano was going to lose catastrophically, in fact it worked out the other way around. Venturis lost the case, and the plaintiffs were awarded a 7-figure judgment. The exact total dollar amount has not yet been revealed, but we will have it soon. This is a judgment that an insolvent, illiquid company like Venturis is all but certainly unable to pay, and that's why most of us who are not leadership believe that Venturis will soon be liquidated.
However, it's important to take a close look below at the incorrect answers, because there's a pattern which seems to repeat itself over and over again (and we seem to be currently in it). I'm confident you'll figure it out.
(A) - It seems many times over the years the "rumor" has floated out of CVBT/Venturis that the company is about to go public. Around the time of the rumor, Grant Gordon's name pops up and people are directed to speak with him about the major transaction that is about to occur. But the event never occurs.
(B) - Likewise we have heard many times that the company is about to close on a sizeable new investment. The numbers keep changing. All that doesn't change, however, is that it never happens. But around the time of the rumor, Grant Gordon's name pops up and people are directed to speak with him about it. But the event never occurs.
(C) - How mahy times have we heard that the clinical trials will be starting "next year"? Too many times to count. And of course not a single clinical trial has been run since 2007. Around the time of the rumor, Grant Gordon's name pops up and people are directed to speak with him about the clinical trials re-starting again. But the event never occurs.
(D) - And of course there's the old favorite, some major partnering deal is about to be announced with a big pharma partner. But gosh, it has never happened just yet! How come? But around the times of the rumor, Grant Gordon's name pops up and people are directed to speak with him about it. But the event never occurs.
(E) - Ah, yes, the number of times it's been "rumored" that some major new investor was about to take a position in this company. But gosh, that never seems to happen.. Yet around the time of the rumor, Grant Gordon's name pops up and people are directed to speak with him about him, and wouldn't you know it, he often has some clients who need cash and are willing to sell stock now even though great news is coming? But the event never occurs.
(G) - Ah yes, we've heard time and time again that a settlement is near for the U.S. government's case against Venturis CEO Calvin Wallen III, for allegedly stealing $14 million. We're always told it's just a corrupt action from the swamps of Louisiana and it's all going to go away soon. But it never does! Around the time of the rumor, Grant Gordon's name pops up and people are directed to speak with him to discuss the coming great developments. But the event never occurs.
The bottom line: We still seem to be in this same pattern. There are "rumors" floating out of the company that some big event is about to occur. If the past is any sort of guide, we know what will happen - nothing. But curiously, Grant Gordon's name has repeatedly popped up yet again (for example, see posts #2445 and #2373), and people are encouraged to talk to him to find out about things. Now mind you, Venturis does not return calls from shareholders, and the company did not hold its 2020 annual shareholders meeting in violation of its bylaws, but one of the top two executives suddenly makes himself available to talk to people. Hmmmm...something tells me that Grant knows people who need cash and unfortunately have to sell their Venturis stock at this time. Well, take a look at this earlier posting:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156783935
And here are the earlier questions in our series:
Question 1: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155716885
Question 2: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155768166
Question 3: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155830431
Question 4: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155887684
Question 5: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156041065
Question 6: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156227658
Question 7: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156355920
Question 8: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156535390
Question 9: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156702737
#IAmThe95%
If you got questions, you should call GGordon. He is busy but he always gets back to me. We talked last week. There is progress. He can give you the details. He didnt mention the former leadership. There are better topics and good things coming into view.
YOU GO LONG!
#IAmThe95%
#$420mToBankrupt
Who knew I was investing in comedy. Watching DM get body slammed is good humour.
There is going be a substantial amount of crow to be eaten very shortly and only one Butterball with an appetite big enough.
#IamThe95%
That cartoon is so funny and sums it up beautifully. Butterball always gets it in the neck from Calvin and Grant. Every time he thinks he may be making headway Calvin and Grant pull the rug from underneath him. Poor old Butterball, always second best.
You are very welcome, D** M******.
Of course a $1.25bn company quoted on the NYSE who have a specialist unit performing valuations for companies & the courts aren't up to Dan Montano's high standards.
The inconvenient truth for Butterball is that a top 20 bank in the world has also been through the valuation & agreed the valuation. OOOOPPPS
THAT'S ALL FOLKS
Grant Gordon, you know perfectly well that Judge Gary Spraker stated that CVBT/Venturis is unable to pay its debts as they become due. Further, I have already previously posted the link to where one can find this in writing, but in response you and/or others keep saying "prove to me he said it" when I already have. I don't respond to trolls. My postings are all available for anyone to review, so feel free to review them. I promise you, you will find the link. That is, if you want to find the link. But we both know you don't.
You also know that Venturis Therapeutics CFO Robert Schleizer stated at one of the annual meetings that the company received a qualified opinion from its auditors with a going concern qualification. I know he said it, because I recorded it. If you think he did not say it, why don't you ask him yourself? Or better yet, why don't you bring a lawsuit for defamation? We both know you won't do either, because he said this with his own mouth. And it's true as well--which is not guaranteed when dealing with the leadership of this company.
Congratulations to Venturis for getting a multi-billion dollar valuation from CBIZ. For those who do not know who CBIZ is (I didn't), the company's website indicates "CBIZ is one of the nation’s leading providers of professional advisory services, focused on accounting, benefits and insurance, HR and payroll solutions." Boy, that's who I'd want valuing my biotech company! What a joke. It honestly makes me laugh thinking about it. What sort of idiots do you think would read that and think that anything they have to say is even a little credible? You might as well have hired Staples to do the same thing, it probably would have been cheaper (Staples also offers accounting, and HR and payroll solutions). But we both know there's a reason why this valuation is not from who it SHOULD be from: Goldman Sachs, Morgan Stanley, etc., etc. And anyone with a single functioning brain cell will also understand how ridiculous that valuation is. Did you know that Bert's Tax Service down the street also does business valuations?
Would you care to tell us all WHY Venturis Therapeutics has not run a single clinical trial since 2007? You seem unwilling to address this issue, yet it's the single most important one.
Thanks again for the tremendous laugh you gave me today about CBIZ. It made my day.
Utter nonsense! There are two narratives here, and the question is, whose narrative will anyone believe? The narrative from a U.S. government bankruptcy judge (Judge Gary Spraker) AND the company's CFO (Robert Schleizer), or your narrative, an anonymous person who says the very opposite of what real people have said on the record?
Judge Spraker stated in the Cardiovascular Biotherapeutics bankruptcy case that CVBT (which renamed itself Venturis Therapeutics) is unable to pay its debts as they become due. That means the company is illiquid. Venturis CFO Robert Schleizer said at the annual shareholders meeting that the company received a qualified opinion letter from its auditors, with a going concern qualification. That means the company is insolvent.
SO YOU'LL BE POSTING COPIES OF COURT TRANSCRIPTS WITH JUDGE SPRAKER'S COMMENTS OR WILL IT BE THE USUAL <<<<<CRICKETS>>>>>>?????
THE AUDIT IS FINISHED NOW & NO GOING CONCERN QUALIFICATION. BOB SCHLEIZER DID NOT STATE THAT AT ANY GENERAL MEETING. YOU WOULD KNOW THAT IF YOU HAD THE ABILITY TO TALK WITH VT MANAGEMENT
You can talk all you want about valuations prepared by H&R Block or whatever other ridiculous sources that do valuations of car washes, restaurants, and oh yeah biotech companies too, but as far as anyone reasonable is concerned, if it doesn't come from Goldman Sachs or someone equally reputable in biotech, it's junk. Did this valuation come from Goldman Sachs, Morgan Stanley, Jefferies, Leerink, Cowen, or anyone like that? Of course not. IT COMES FROM A PUBLIC COMPANY, CBIZ, & WAS THEN VERIFIED BY A TOP INVESTMENT BANK WHO VT HAVE SIGNED UP WITH. ARE CBIZ NOT LEGITIMATE, WALLY???
Venturis Therapeutics is all but worthless. Why do I say that?
FACT: This zombie company has not run a single clinical trial since 2007. Right there, that puts to rest any claims that Venturis is a valuable company. It's not--it's a dead company.
FACT: Venturis just lost a 7-figure judgment that it all but certainly can not pay. And the company was caught lying about it.
6 FIGURE JUDGEMENT WHICH CAN BE PAID AT A TIMING CHOSEN BY VT. GUESS WHEN THE TIMING OF THAT WILL BE???? smile smile smile
AN AFFILIATE OF VT HAS A $1.75M COURT JUDGEMENT AGAINST HERR BUTTERBALL MONTANO. THEY ARE NOW GEARING UP TO GO AFTER OUR AFFECTIONATELY KNOWN EX-CEO, CONMAN DAN, TO COLLECT. BUTTERBALL'S BANKRUPTCY WON'T SAVE HIM FROM HIS CREDITORS. OUCH!!
FACT: This company is facing a relentless collection effort and is about to be liquidated one way or another.
PROOF/EVIDENCE????
FACT: The company's CEO is awaiting a trial bought by the U.S. government for allegedly stealing $14 million from his previous company. There are no investors who are going to put a dime into Venturis until this matter is resolved one way or another. Hopefully Calvin Wallen III clears his good name. But that's highly unlikely given the government's overwhelming evidence and case against him. I know, because I've read the documents. And if you haven't but would like to, see the links below.
SORRY, WALLY, THE CASE IS BEING NEGOTIATED THRU COURT MANDATED MEDIATION & HAS BEEN FOR OVER 2 MONTHS.
End of discussion. Have a nice weekend!
THANKS WALLY, I INTEND HAVE A GREAT WEEKEND. IT GOES WITHOUT SAYING THAT EVERYONE ON THE MESSAGE BOARD WISHES YOU THE VERY SAME.
No it won't be as PR is PR it's not necessarily fact. I'll be pleasantry surprised when I look at my share account and the shares are trading and worth something. Everything else is rumour and hearsay as always.
Exactly. This.
The science has not changed. The company has only improved upon the data. Added pre-clinical information. Licenced data from Merck.
As I said before. Multiple reputable investment banks have valued CVBT in the billions. The only thing ever preventing that was previous mismanagement.
I get the company, since the beginning, has been a trainwreck of monumental proportions. Question: Were the benefits of the FGF-1 protein with regard to the heart, angiogenesis, pressure ulcers and decubitus ulcers, etc lies too? What about the German trials showing people at deaths door active and doing well? What about the 3 week timeframe for complete closure of bed sores? This is why I got behind CVBT in the first place. Dan Montano was a blowhard but the results seemed real...what about Peter Jennings? Was he lying too?
The only going concern is Zhittya's WORLD CLASS SOCIAL MEDIA CAMPAIGN that appears to be on life support with their hundred, yes you read that right hundred followers.
No emails, no posts, no videos, no social.
Only Dan shouldering up to the latest bingo winner trying to get her to invest the $60 bucks she just won in her church basement bingo.
"Hey Marge, I'm Dan. Did you know Zhittya means BULLCRAP in Ukraine?"
Hahahahahah
#IAmThe95%
#Danopoloy
#$420mToBankrupt
So here's some more information about the company CBIZ who has allegedly given a multi-billion dollar valuation to Venturis Therapeutics.
From the company's website, front page:
CBIZ is one of the nation’s leading providers of professional advisory services, focused on accounting, benefits and insurance, HR and payroll solutions.
In large font and bold letters the company lists its expertise:
Accounting
Insurance
Advisory
HAHAHAHAHAHAHAAHA!!!!!
I guess that's who I'd want to have value my biotech company credibly, a company that is focused on accounting, benefits and insurance, HR and payroll solutions. This is beyond hysterical!! I literally was laughing so hard when I read this.
Venturis Therapeutics might as well have hired H&R Block to perform its valuation. Heck, at least everyone has heard of them. And they may be more credible in biotech than CBIZ.
It's like wanting to serve a wonderful French meal for dinner guests, and going to McDonalds for recipes.
Thanks to Venturis Therapeutics for starting my weekend with a huge laugh and a gigantic smile on my face. This is incredibly funny.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156837193
The bankruptcy of Venturis Therapeutics
1) It's awesome! Faced with facts about the dire situation at Venturis which put to rest that the company is both insolvent and illiquid, its supporters can only deny that bankruptcy judge Gary Spraker said that Venturis is illiquid and CFO Robert Schleizer said that it received a going concern qualification from its auditors. When the best "defense" that can be offered is that these individuals did not say what they PUBLICLY STATED, it's over.
2) CBIZ is the source of this company's valuation? HAHAHHAHAHAHAHA It says everything that Venturis Therapeutics cites a valuation from CBIZ (who???), not Goldman Sachs, Morgan Stanley, Bank of America Merrill Lynch, Jefferies, Cowen, Leerink, etc., whose valuations would be taken seriously. It's self-discrediting.
3) Let's go back to the key fact: VENTURIS THERAPEUTICS HAS NOT RUN A SINGLE CLINICAL TRIAL SINCE 2007. That's 13+ years for those that don't want to do the math. End of story. This is a dead, broken company. Humpty Dumpty can not be put back together again.
4) For those of you who didn't see it, a high-placed insider who left the company in frustration spilled the beans about the company's desperate condition:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155941891
5) Does anyone put money into a company where the CEO is accused by the U.S. government of stealing $14 million from his previous company? Hell no! But that's the situation here. The U.S. government has accused Calvin Wallen III of stealing $14 million from his previous company. Mr. Wallen has successfully delayed his trial for 3 years now (with an assist from coronavirus), but the day of reckoning is coming soon. A TX bankruptcy attorney I spoke with who is not involved with this case but is familiar with its outlines said to me, "the govesrnment does not lose cases like this." But hey, why not read it for yourself?
Tauren Exploration, Inc. Liquidating Trust vs. Calvin Wallen III:
https://www.pacermonitor.com/public/case/24021776/Tauren_Exploration,_Inc_Liquidating_Trust_v_Wallen,_III
Tauren Exploration, Inc. Liquidating Trust vs. Pandale Holdings, Inc. et. al:
https://www.pacermonitor.com/public/case/24021775/Tauren_Exploration,_Inc_Liquidating_Trust_v_Pandale_Holdings,_Inc_et_al
Tauren Exploration, Inc. Liquidating Trust v. Fossil Operating, Inc. et al:
https://www.pacermonitor.com/public/case/24021777/Tauren_Exploration,_Inc_Liquidating_Trust_v_Fossil_Operating_Inc_et_al
I'm not a believer in either story really but I'm a much bigger fan of current managements abilities than the formers. Very skeptical but I'd wager ca and gg are much more capable than the former unstable butterball
ALL THAT MATTERS IS THAT IT MAKES SENSE TO THE 95% OF SHAREHOLDERS WHO VOTED THE FORMER FAILED CVBT CEO OUT
$420M TO ZERO
PENTHOUSE TO THE POOR HOUSE
CORRUPT TO BANKRUPT
POOR HOUSE TO THE BIG HOUSE
A BRUIN ALWAYS USES A TROJAN
Utter nonsense! There are two narratives here, and the question is, whose narrative will anyone believe? The narrative from a U.S. government bankruptcy judge (Judge Gary Spraker) AND the company's CFO (Robert Schleizer), or the narrative of anonymous individuals who say the very opposite of the public record?
Judge Spraker stated in the Cardiovascular Biotherapeutics bankruptcy case that CVBT (which renamed itself Venturis Therapeutics) is unable to pay its debts as they become due. That means the company is illiquid. Venturis CFO Robert Schleizer said at the annual shareholders meeting that the company received a qualified opinion letter from its auditors, with a going concern qualification. That means the company is insolvent.
Venturis supporters can talk all they want about valuations prepared by H&R Block or whatever other ridiculous sources that do valuations of car washes, restaurants, and oh yeah biotech companies too, but as far as anyone reasonable is concerned, if it doesn't come from Goldman Sachs or someone equally reputable in biotech, it's junk. Did this valuation come from Goldman Sachs, Morgan Stanley, Jefferies, Leerink, Cowen, or anyone like that? Of course not.
Venturis Therapeutics is all but worthless. Why do I say that?
FACT: This zombie company has not run a single clinical trial since 2007. Right there, that puts to rest any claims that Venturis is a valuable company. It's not--it's a dead company.
FACT: Venturis just lost a 7-figure judgment that it all but certainly can not pay. And the company was caught lying about it.
FACT: This company is facing a relentless collection effort and is about to be liquidated one way or another.
FACT: The company's CEO is awaiting a trial bought by the U.S. government for allegedly stealing $14 million from his previous company. There are no investors who are going to put a dime into Venturis until this matter is resolved one way or another. Hopefully Calvin Wallen III clears his good name. But that's highly unlikely given the government's overwhelming evidence and case against him. I know, because I've read the documents. And if you haven't but would like to, see the links below.
End of discussion. Have a nice weekend!
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156705047
If you'd like to learn more about the upcoming trial of Venturis CEO Calvin Wallen III, who is accused by the U.S. government of stealing $14 million from his previous company, here are the links to the court records in these related cases:
Tauren Exploration, Inc. Liquidating Trust vs. Calvin Wallen III:
https://www.pacermonitor.com/public/case/24021776/Tauren_Exploration,_Inc_Liquidating_Trust_v_Wallen,_III
Tauren Exploration, Inc. Liquidating Trust vs. Pandale Holdings, Inc. et. al:
https://www.pacermonitor.com/public/case/24021775/Tauren_Exploration,_Inc_Liquidating_Trust_v_Pandale_Holdings,_Inc_et_al
Tauren Exploration, Inc. Liquidating Trust v. Fossil Operating, Inc. et al:
https://www.pacermonitor.com/public/case/24021777/Tauren_Exploration,_Inc_Liquidating_Trust_v_Fossil_Operating_Inc_et_al
Patents at the Core: the Biotech Business
World Intellectual Property Organisation - WIPO
“Anyone, I would imagine, who has tried to create a biotech company knows just how important
patents are. You learn this when you’re studying, and again at your first job, and if you haven’t
done so before, you realize it the first time you meet potential investors.”
Mads Øvlisen,Chairman of the Board of Directors, Novo Nordisk
But there again what does the chairman of Novo Nordisk know about patents. They have only been using patents to protect their property since 1923 - GUFFAW!!
Let's not forget the value of VT is in their patents.
20 patents across 7 clinical and pre-clinical indications. 4 pending related to COVID.
Remember when someone tried to convince everyone how useless biotech patents are?
Major Biotech companies disagree. 848 patents on 12 drugs. Twelve.
But who wants to talk about irrelevant Gary Spraker? Hahahahhaha
Personally I'm glad the current team knows what they are doing and protecting their IP with patents.
https://accessiblemeds.org/resources/blog/pharmaceutical-patent-abuse-infinity-and-beyond
We are, however, increasingly seeing evidence of how the patent system is being used to tip the balance and delay patient access to a point well beyond what Congress intended. In a recent report from I-MAK, the top 12 brand drugs on the market last year are protected by a total of 848 patents (71 per drug) providing an average of 38 years without generic competition. A few examples from the report:
The world’s top-selling brand drug, Humira, treats arthritis and other chronic conditions. On the market since 2002, 132 patents block competition for up to 39 years.
One of the most prescribed cancer treatments, Revlimid, was approved by the FDA in 2005. The patent thicket consists of 96 patents providing potentially 40 years without competition.
Diabetes patients who rely on the insulin treatment, Lantus, may not see a generic alternative for 37 years due to the 49 patents issued.
There is no question that several of these patents represent true innovation. New patient populations benefit from the same drug being used to treat a different condition, for example. But the expansive use of the patent system to build barriers to generic and biosimilar competition results in patients paying higher drug prices for longer.
SO IT'LL BE A PLEASANT SURPRISE WHEN YOU READ THE UPCOMING PR FROM VT
#Iamthe95%
#$420mToBankruptcy
#DanOpoly
#FAILEDCEO
Here we go with the Judge Gary Speaker nonsense again. You might as well get Zhittya to put that into their fictitious world class social media campaign. That's how important it is.
Dan hopes they are insolvent but he is mistaken. If he was correct or if these fictitious claims about insolvency meant anything, the involuntary BK would not have been thrown out. Instead let's just keep repeating this worthless irrelevant conjecture.
Maybe eventually you will convince yourself it's true and means something while Dan waits years for his measley payment.
In the meantime VT laughs at Dan and the claims of insolvency while they march forward raising money in preparation for a relist.
#Iamthe95%
#$420mToBankruptcy
#DanOpoly
Surfer, if you look at the video by the Singaporean guys you get chapter & verse on the London IPO which Butterball Montano blew up.
It also highlights the mental state of Butterball.
History of a FAILED CEO
I've written the money off long ago and not expecting anything, it's not a huge amount so I'll just see what happens. Nothing I suspect!
I respect your cynicism Surfdude1. If you go back a few years and look at some of my posts, you will see I was cynical and equally frustrated.
It wasnt until I received some information and read the court transcripts and spoke with company representatives and others who have also spoken with them and I can see that there is a lot going on that is not public and I am now hopefully anticipating a good outcome.
All of our accounts still show zero but that is because it is illiquid, not because it is worthless.
For example, if you really wanted to, you could most likely find a buyer for your shares if you were willing. Whether an official transaction or pledging control and beneficial ownership.
At this moment in time and as far as I can see the longer term too, there is no value in VT! It's all hearsay and conjecture. VT is worth zilch, nought, nothing, diddly squat etc. etc. Prove otherwise and I'll be less cynical.
Thank you Dan, Laub and Jacobs for showing everyone the value. You're actions prove there is something worth fighting for here. That's why they have spent a decade trying to get "their" company back.
That's why Laub admitted under oath he was trying to destroy VT.
If VT is already dead, the former CEO and cronies certainly doesn't think so proven by their actions. A company that is already dead doesn't need to be "destroyed" as stated in Laubs testimony.
And I believe Laub because he just invested $150 million in Zhittya. If Zhittya is worth $150m with no patents, no IP, no trials, no data, 4 employees, a failed and bankrupt CEO, well then it's quite easy to see the value in VT.
The real value of Venturis Therapeutics.
Multiple times, multiple investment banks and multiple underwriters have given VT a valuation over a billion dollars.
First, at the initial US IPO, then again during the London IPO that Dan screwed up.
So at least twice, major backers have agreed that there is value here.
Additionally, Dan the former CEO fought hard to keep control of the company. Why? Because it was worthless? I think not.
If the former CEO thought it was worthless why did he start Zhittya who is trying to copy VT and be a me too player and do almost the exact same thing as VT?
VT has more patents, more data than they did when they were given those high valuations by prominent and reputable investment banks. They have licenced an additional molecule.
The balance sheet is fixed and the cancer of the former CEO and his cronies have been embarrassingly removed and dealt with.
VT is worth more today than it ever has simply by ridding itself of the former failed leadership.
But let's not overlook the improved balance sheet also.
It is easy to see how institutions are giving VT the valuations being discussed when you think about it.
The science hasn't changed. The company has moved slowly but it has moved ahead and is further along than it was at it's IPO, and further along when Dan ruined the London IPO.
#Iamthe95%
Two Very Significant Venturis Therapeutics Developments
There have been two major news developments at Venturis Therapeutics in recent weeks (formerly Cardiovascular Biotherapeutics or CVBT), but as these are so important (and so telling) it would be a good idea for everyone to take a close look at the details here because they matter so much.
1) Venturis caught in another lie: Venturis Therapeutics was AGAIN caught red-handed trying to cover up bad news. This is a pattern with the dishonest leadership team of Calvin Wallen III and Grant Gordon, where Venturis says something publicly and it subsequently blows up on them, and then they try to pretend it was never said in the first place. Unfortunately Venturis’s mindset about covering things up is pre-Internet when search engines didn’t exist. But what would you expect from dishonest uneducated dropouts, who between the two of them have only one high school diploma and no college or advanced degrees? But ooops...you won't find those facts in their bios.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156561987
2) An Insider Tells All: A Venturis Therapeutics insider who left the company spoke to someone I know who is also a shareholder, and he/she spilled the beans on what’s really going on at Venturis / CVBT. Be sure to read this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155941891
The bottom line: This zombie company has suffered a catastrophic 7-figure loss in a binding arbitration case that it now pretends did not happen, and that it can not pay. Once the final dollar figure is declared by the judge sometime later this month (July 2020), an aggressive collection effort is likely to commence. I believe it will result in either the liquidation of Venturis Therapeutics or a bankruptcy filing that results in the same. All roads lead to liquidation and the end of Venturis Therapeutics, and soon.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156705047
We all know shittya sux but this board is about cvbt. Bashing former leadership doesn't do anything for my investment roi.
And we all know that Shittya hasn't run any clinical trials, either. And we also know the 5% who were against the former failed CEO being voted out are very supportive of Shittya; an all but defunct, bankrupt, fraudulent so-called biotech company trying to raise money at money shows. I wonder why this is?
Im glad you asked. After being delisted. The crack CEO Dan Montano had plans to re-list the company on the new Alternative Investment Market exchange in London. The company incurred $1.2 million in expenses related to this effort as indicated in this SEC filing (search London, multiple mentions).
https://www.sec.gov/Archives/edgar/data/1303497/000114420408026175/v110520_10k.htm
Of course, Dan flaunted the rules of the listing exhange and gave a public interview about CVBT during a BLACKOUT period.
The IPO was cancelled.
#Iamthe95%
#$420mToZero
What was the London IPO?
I remember the conference call right before the vote where Dan was BEGGING and SOBBING to shareholders not to vote him out.
It was pretty pathetic.
He presented no plans. Had no path forward. Couldn't answer half the questions asked of him. Got angry and started screaming about having no money.
Of course he didn't tell us about the botched London IPO while he begging us to keep him. Many of us found out about that after.
I would vote him out again if I could.
I'm far more interested in Venturis Therapeutics' plans for its (non-existent) clinical trials. Did you know that Venturis has not run a single clinical trial since 2007? I suspect not. But I'm happy to keep reminding stakeholders of this critical fact. It would seem to me this should be a lot more concerning to Venturis shareholders than frankly anything else.
Why is it that the company has nothing to say about clinical trials? Isn't that supposed to be the whole point of a development-stage biotech company?
But I believe none of this matters, as Venturis is all but certainly going to be liquidated, and very soon:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156705047
Understanding Venturis Therapeutic's AI Pathway, Part 2
I think the AI indication (Alcoholic Impotence) for Venturis Therapeutics's drug is one of the most important opportunities the company has. Why? Because look at the valuations on Wall Street. They are valuing companies at incredible premiums that are developing treatments in significant disease areas where there are none, or represent a major breakthrough over standard of care. This is potentially both.
Dr. Angus Innes has published a validated algorithm that is used to screen AI (Alcoholic Impotent) patients, and I believe this algorithm has significant implications for Venturis Therapeutics, as it will greatly assist in screening/recruiting patients for the company's clinical trials (assuming Venturis doesn't get liquidated soon, which is likely to happen). Dr. Innes's algorithm is a scoring system that takes the number of years the alcoholic has been drinking at an alcoholic level (1-70), multiplied by the number of blackouts the alcoholic experiences each year (1-200), multiplied by the number of months each year the alcoholic drinks at all (1-12). If the score is less than 150, there is hope. But if the score exceeds 150, statistical and regression analysis indicates the alcoholic is never going to have children on his own. The only hope for such an alcoholic is if someone develops a therapeutic intervention.
So let's test the algorithm. It's well known that one of the members of Venturis Therapeutics's leadership team suffers from AI and has been unable to bear any children even with multiple wives. Let's apply Dr. Innes's algorithm to his circumstances to see what it indicates.
A) Number of years the alcoholic has been drinking at an alcoholic level: Well, this individual turns 58 in 2020, and he's reportedly been drinking at an alcoholic level since his early teens (and probably earlier). So it's safe to say the number here is 45.
B) The number of blackouts the alcoholic experiences each year: Rumor has it that this alcoholic is good for at least one blackout per week. So it's safe to say the number here is 52.
C) The number of months per year the alcoholic drinks: This one is easy: 12.
Analysis of the results: According to Dr. Innes, to reach the screening score, we would multiple 45 x 52 x 12. That equals 28,080. Now let's compare this to Dr. Innes's findings. Dr. Innes indicates that any score over 150 indicates alcoholic impotence. My goodness..this score is so far over that threshhold. Does it set a record? Only Dr. Innes can tell us that.
The bottom line: I believe that Venturis Therapeutics has found Patient #1 for its AI clinical trial.
If you did not see it, here is Part 1 of this series:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156636596
And if you'd like to understand why Venturis Therapeutics is on the verge of liquidation, take a look at this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156705047
Coming soon: Part 3
BEWARE: Someone is apparently trying to dump their Venturis Therapeutics stock onto unsuspecting investors, and given the reference to "GG" it may well be Grant Gordon. Venturis is an insolvent, illiquid, failed company that is facing imminent liquidation after having lost a 7-figure judgement. I believe anyone who purchases stock in this company through a private stock transaction (see post #2373) is going to lose 100% of their investment, and in near-record time.
Make sure you read about the company's imminent demise:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156705047
Make sure you read about recent developments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156636621
A public service message brought to you by Walhall.
Haha very funny and very apt. Going nowhere
BREAKING NEWS: It appears that Dan has been kicked off the Money Show.
There is no mention of his departure on the website. They have scrubbed all mention of Dan and Zhittya.
I can only assume he fell in arrears in his dues. Apparently he wasn't raking it as well as he hoped when he passed the collection plate at the end of his talk. Those that were awake only dropped in nickles.
I regret that I did not get a chance to see Dan spin up a room of blue hairs faster than a BOGO at Denny's.
The master biotech investor, bankrupt, anonymous poster extrordinarre.
I'm sure there's some archive footage in Zhittya's invisible social media campaign somewhere. Good luck getting to their website though. I heard the internet traffic is swamped with the literal hundreds of Zhittyas blue hair followers, just waiting for the next masterful digital marketing piece to drop.
I'm about as confident cvbt will succeed as I will be bitten by a shark....and I live in chicago.
None Of This Had To Happen: Part IV
But it did happen, former failed leadership. So guess what? Someone is bankrupt and headed to the Big House while others are bankrupt and headed to the Poor House. Couldn't have happened to a better bunch
$420,000,000 POOF!! GONE!!
I'd love to see something tangible happen but it's very unlikely. All we get is bs on this board. We'll still be here in 10 years time with shares still worth zilch and the same old bs from both sides. I hang on in hope, bit like my football team, they're odds on to be relegated but I still hope against hope with no rational logic to fulfill that hope.
It hasn't been 10 years. It has been 6. 2014 is when we voted Dan out.
#Iamthe95%
The previous CEO had damaged the company. Wallen took a few years figuring out what was there. How to get a return. He ended up up with hundreds of boxes of files and such, physical and electronic. He needed new science people
He renegotiated and cleaned the balance sheet. He spent two years under the threat if invol bankruptcy thanks to the former CEO who obviously doesn't give a single crap about the shareholders.
The legal stuff was just resolved this year with Dan being awarded a couple of bucks compared to $420 million he would have been worth. He got a mere 3 months salary. HAHAHA
#$420mToZero
Now that the legal strife is done they have licenced a new molecule and have new patents.
The neighsayors are louder than ever because they are MAD.
Not because their investment is worthless but because their shares were lost due to their own incompetence.
Now the biggest shareholder is our CEO and if half the rumor is true, longs are in for a nice gain. The only way Calvin gets his money back is to make VT successful.
Stay tuned.
Prove him wrong. Trials and relisting. 10 years of bs so far.
I can just picture Conman Dan screaming and cursing at the computer screen right now. He's frothing at the mouth with crumbs from his Ding Dongs and Twinkies all over his face, keyboard and screen Hahaha....
Yep let's see some progress, preferably a relisting, nothing else is worth anything!
Probably right, more patents. Big deal. How about trials or relisting? Maybe a SPAC merger to go public? Otherwise that good news is more marshmallow fluff.
I'll believe it when I see it
I've got fantastic news for you, Walhall. It's only a 6 figure sum not 7 figures. You know the old saying "read the small print". In our case the small print reads that VT can pay Butterball Montano & Creepy Hack Facobs when it suits the cash-flow of VT. So, if the "dynamic duo" are lucky they may get some $$$ in 2121-2122. I know you will be relieved to know that Walhall. PHEW!!
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3647
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |